Roivant's Matt Gline on the success of Telavant, Immunovant's FcRn program, and his expectations for the company's cash usage

blonca9
Jan 22, 2024
1 min read

Matt Gline reflects on learnings from the Telavant success, why he thinks Immunovant's FcRn might be best in class, and how Roivant's asset hunting has been going lately.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Roivant's Matt Gline on the success of Telavant, Immunovant's FcRn program, and his expectations for the company's cash usage

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight